+Compare
XERS
Stock ticker:
NASDAQ
AS OF
Aug 5 closing price
Price
$1.67
Change
+$0.07 (+4.38%)
Capitalization
226.34M

XERS Xeris Biopharma Holdings Forecast, Technical & Fundamental Analysis

a developer of ready-to-use, liquid-stable injectables
Industry Biotechnology
AI
A.I.Advisor
a Summary for AAPL with price predictions
12:00 AM EDT Aug 05, 2022

XERS's RSI Indicator ascending out of oversold territory

The RSI Indicator for XERS moved out of oversold territory on July 19, 2022. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In 26 of the 31 cases the stock moved higher. This puts the odds of a move higher at 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 04, 2022. You may want to consider a long position or call options on XERS as a result. In of 69 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for XERS just turned positive on July 19, 2022. Looking at past instances where XERS's MACD turned positive, the stock continued to rise in of 30 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XERS advanced for three days, in of 217 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XERS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for XERS entered a downward trend on July 27, 2022. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.346) is normal, around the industry mean (26.217). P/E Ratio (0.000) is within average values for comparable stocks, (100.146). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.703). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (2.565) is also within normal values, averaging (316.522).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. XERS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XERS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

AI

View a ticker or compare two or three

XERS
Buy/Sell Ratings
 
 
Technical Analysis# Of IndicatorsAvg. Odds
   
   
 
AI
A.I. Advisor
published Earnings

XERS is expected to report earnings to fall 14.00% to -21 cents per share on August 10

Xeris Biopharma Holdings XERS Stock Earnings Reports
Q2'22
Est.
$-0.22
Q1'22
Missed
by $0.01
Q4'21
Missed
by $0.21
Q3'21
Missed
by $0.05
Q2'21
Missed
by $0.11
The last earnings report on May 11 showed earnings per share of -25 cents, missing the estimate of -24 cents. With 709.37K shares outstanding, the current market capitalization sits at 226.34M.
AI
A.I. Advisor
published General Information

General Information

a developer of ready-to-use, liquid-stable injectables

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
180 North LaSalle Street
Phone
+1 844 445-5704
Employees
294
Web
https://www.xerispharma.com

Interesting Tickers

1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DMVAX22.490.11
+0.49%
BNY Mellon Select Managers Sm Cp Val A
CAAIX41.660.06
+0.14%
Ariel Appreciation Institutional
KMDVX26.570.03
+0.11%
Keeley Mid Cap Dividend Value A
CABGX14.62-0.04
-0.27%
Multi-Manager Growth Strategies Inst 3
PAHWX6.48-0.08
-1.22%
PGIM Jennison Intl Sm-Md Cap Opps A

XERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, XERS has been loosely correlated with PDSB. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if XERS jumps, then PDSB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XERS
1D Price
Change %
XERS100%
+4.37%
PDSB - XERS
46%
Loosely correlated
+3.31%
AFMD - XERS
45%
Loosely correlated
+0.92%
LGND - XERS
45%
Loosely correlated
-0.41%
ZNTL - XERS
43%
Loosely correlated
+0.07%
PRTA - XERS
42%
Loosely correlated
+2.63%
More